CTI BioPharma, the licence holders for Pacritinib, has requested all patients stop taking pacritinib after it received information from the U.S. Food and Drug Administration (FDA) regarding PERSIST-1 and PERSIST-2 drug trials.
If you are enrolled on the PERSIST-1 and PERSIST-2 trials and have been prescribed Pacritinib you should have been contacted by your trial team and given instructions regarding stopping the Pacritinib.
Hopefully there will still be the opportunity to use this drug in the future as there was clear evidence of benefit for many patients but this decision has been taken with regard to balance of risks.
Fast-track activation accelerates clinical trial for myelofibrosis and PV treatment
Great group of videos 
Clinical Trail Updates for Patients
